top of page

Free Biopharma Daily Stock Updates - 05/02/22

$XBI $76.78 | +4.0%

BiopharmIQ offers pro members full access to FDA Catalyst Calendar, PDUFA's, Biotech Stock Ideas.

Table of Contents:

Covid Updates

$SRNE +7.3% Sorrento Announces Full Enrollment of Phase I Study of Intranasal STI-9199 (COVISHIELD™ IN), a Potent Neutralization Antibody Against Omicron BA.2 and All Variants of Concern. source

Pipeline Updates

$ACAD +6.0% Acadia Pharmaceuticals Announces FDA Advisory Committee Meeting to Review Resubmission of Supplemental New Drug Application for NUPLAZID® (pimavanserin) for the Treatment of Alzheimer’s Disease Psychosis Scheduled for June 17, 2022 source


$APLS +3.3% Apellis Announces Detailed 18-Month Results from Phase 3 DERBY and OAKS Studies of Pegcetacoplan for Geographic Atrophy (GA) at ARVO Annual Meeting source

$IKNA -2.6% Ikena Oncology and Vall d’Hebron Institute of Oncology Announce Research & Development Collaboration.

$DNLI +5.7% Denali Therapeutics Announces Achievement of RIPK1 Milestone for Phase 2 Clinical Trial Initiation in ALS by Sanofi. source

$TCRT -7.3% Alaunos Therapeutics Doses First Patient in TCR-T Library Phase 1/2 trial for the Treatment of Patients with Solid Tumors. source

$VERU -12.4% FDA Has Granted Veru a Pre-Emergency Use Authorization (EUA) Meeting Date for Positive Sabizabulin Phase 3 COVID-19 Study. source

$RYTM +0.6% Rhythm Pharmaceuticals Presents New Data from Phase 3 Trial Evaluating Setmelanotide in Patients with Bardet-Biedl Syndrome (BBS) at the Pediatric Endocrine Society (PES) 2022 Virtual Annual Meeting. source

$MDNA +5.6% Medicenna Announces New Clinical Data Showing Dose-Dependent Stimulation of Anti-Cancer Immune Cells with MDNA11 in the Phase 1/2 ABILITY Study. source

$VBIV +7.2% VBI Vaccines Announces European Commission Marketing Authorisation for PreHevbri™, a 3-Antigen Adult Hepatitis B Vaccine. source

$GRTX +10.1% Galera Announces Topline Results from Phase 2a AESOP Trial of Avasopasem for Chemoradiotherapy-Induced Esophagitis. source

$ZYNE +3.6% Zynerba Pharmaceuticals Presents Long-Term Safety and Efficacy Data of Zygel™ in Children and Adolescents with Fragile X Syndrome (FXS) at the 2022 Society of Biological Psychiatry Annual Meeting. source

$AXSM +7.2% Axsome Therapeutics Receives FDA Complete Response Letter for New Drug Application for AXS-07 for the Acute Treatment of Migraine. source

$TARS -23.5% Tarsus Announces Positive Topline Data from Saturn-2 Phase 3, the Second Pivotal Trial of TP-03 for the Treatment of Demodex Blepharitis, and Expects to File a New Drug Application This Year. source

$CHRS +7.1% Coherus and Junshi Biosciences Receive Complete Response Letter from U.S. FDA for Toripalimab BLA. source

$SAGE +3.4% Sage Therapeutics and Biogen Initiate Rolling Submission of New Drug Application (NDA) to U.S. Food and Drug Administration for Zuranolone for the Potential Treatment of Major Depressive Disorder (MDD). source

$HCM -19.0% HUTCHMED Receives Complete Response Letter from the U.S. FDA for Surufatinib for the Treatment of Advanced Neuroendocrine Tumors. source

$IDYA +2.4% IDEAYA Biosciences Receives Orphan Drug Designation for Darovasertib, a PKC Inhibitor, for the Treatment of Uveal Melanoma. source

$HZNP -0.5% Horizon Therapeutics plc Receives European Commission (EC) Approval of UPLIZNA® (inebilizumab) for the Treatment of Adults With Neuromyelitis Optica Spectrum Disorder (NMOSD). source

$ADVM +3.7% Adverum Biotechnologies Presents Additional Efficacy and Safety Data from the OPTIC Trial of ADVM-022 in Wet AMD at the ARVO 2022 Annual Meeting. source

$KALA +17.0% Kala Pharmaceuticals to Present Clinical Data for KPI-012, its Mesenchymal Stem Cell Secretome Product, for the Treatment of PCED at the 2022 ARVO Annual Meeting. source

$MIST -7.5% Milestone Pharmaceuticals Announces Presentation of Data from Phase 3 NODE-302 Study of Etripamil for the Treatment of PSVT. source

$RLMD +3.0% Relmada Therapeutics Announces Publication of REL-1017 Preclinical Data in Frontiers in Pharmacology. source

$SUPN +3.5% Supernus Announces FDA Approval of Qelbree® for the Treatment of ADHD in Adults. source

$MYOV +6.2% Myovant Sciences Announces European Commission Approval for ORGOVYX® (relugolix) for the Treatment of Advanced Hormone-Sensitive Prostate Cancer. source


Want to get weekly catalyst updates?

*We never spam you - unsubscribe anytime*


Business Updates



Posted by FS/JM

bottom of page